Granules India has officially scheduled an Extraordinary General Meeting (EGM) for January 22, 2026 at 11:30 AM IST through video conferencing to seek shareholder approval for its comprehensive ₹1,762.50 crore fundraising initiative through preferential allotment.

EGM and Voting Details

The pharmaceutical company has announced detailed procedures for the upcoming EGM, with remote e-voting commencing from January 19, 2026 (9:00 AM IST) and concluding on January 21, 2026 (5:00 PM IST). Shareholders holding shares as of the cut-off date of January 15, 2026 will be eligible to participate in the voting process.

Convertible Warrants Issuance

The board has approved the issuance of up to 2.50 crore convertible warrants at ₹585.00 per warrant, targeting both promoter group and non-promoter investor categories. The warrants are convertible into equivalent equity shares within 18 months from allotment date.

Equity Shares Component

The company will also issue 51.28 lakh fully paid-up equity shares exclusively to non-promoter investors at ₹585.00 per share, raising ₹300.00 crores. The equity shares will be distributed among nine institutional investors including 360 ONE Equity Opportunity Fund, Public Sector Pension Investment Board, and other fund houses.

Investor Allocation and Fund Utilization

The convertible warrants will be allocated among five investors, with Mrs. Chigurupati Uma Devi (Promoter) receiving the majority allocation of 2.49 crore warrants, resulting in a post-issue holding of 12.51%. The fundraising proceeds will be utilized for funding business operations, vendor payments, and general corporate purposes.

Regulatory Compliance and Approvals

The fundraising initiative is subject to regulatory approvals and shareholder consent. The relevant date for the preferential issue under SEBI ICDR Regulations is December 23, 2025. The company has appointed a monitoring agency to oversee the utilization of proceeds exceeding ₹100 crores as per regulatory requirements.

Shareholders can access the complete EGM notice and related documents on the company's website at granulesindia.com. The initiative represents a strategic capital raising approach combining multiple instruments to strengthen the pharmaceutical company's financial position for organic and inorganic growth opportunities.

Granules India Limited announced that its wholly owned subsidiary Granules Pharmaceuticals Inc. has received tentative approval from the U.S. Food and Drug Administration (FDA) for its second generic ADHD medication within weeks. The latest approval, announced on January 8, 2026, covers generic Amphetamine Extended-Release Tablets with 180-day exclusivity, marking a significant milestone in the company's central nervous system therapeutic expansion.

Latest FDA Approval with Market Exclusivity

The recent tentative approval covers generic Amphetamine Extended-Release Tablets in four strengths, positioning it as the generic equivalent of DYANAVEL XR. The FDA has determined that Granules' ANDA is eligible for 180-day exclusivity, providing the company with a competitive advantage in this specialized market segment.

Previous ADHD Drug Approval

Granules previously received tentative approval on December 22, 2025, for Amphetamine Extended-Release Orally Disintegrating Tablets, the generic equivalent of ADZENYS XR-ODT. This earlier approval covers six different strengths and targets a significantly larger market opportunity.

Strategic Market Positioning

Both products are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD), positioning Granules to serve different segments of this therapeutic market. The combined market opportunity of approximately USD 213.00 million demonstrates the company's strategic focus on high-value, complex generic formulations with limited competition.

Management Commentary and Strategic Vision

Dr. Krishna Prasad Chigurupati, Chairman and Managing Director, emphasized that having a product eligible for 180-day exclusivity strongly validates Granules' long-term strategy of building a differentiated portfolio of complex generics. He highlighted that this achievement reinforces the company's commitment to strengthening its presence in the central nervous system therapeutic space while enhancing value creation in the U.S. generics market.

The consecutive approvals within weeks demonstrate Granules' expanding capabilities in complex formulation development and regulatory execution, reinforcing the company's ability to identify, develop, and progress technically challenging products that deliver meaningful differentiation and long-term value in the U.S. generics market.